Vertex Pharmaceuticals Incorporated (VRTX)

In the past six months, Vertex Pharmaceuticals' stock has experienced several events and analyst activities. As of October 23, 2025, the share price was $422.63, a 10.44% decline from October 24, 2024. The stock's 12-month low is $362.50 and its 12-month high is $519.88. In Q2 2025, Vertex reported $4.52 EPS, surpassing estimates, with revenue at $2.94 billion, an 11.3% year-over-year increase driven by new product launches. Several analysts adjusted their ratings and price targets, resulting in a consensus rating of "Moderate Buy" and an average target price of $494.38. Director Bruce I. Sachs acquired 5,000 shares at $389.68 per share. Vertex is expected to report Q3 2025 earnings of $4.55 per share, with revenues projected at $3.04 billion. Vertex management participated in several healthcare conferences and presented new data across its cystic fibrosis medicine portfolio.

The provided search results do not contain specific information regarding the demand seasonality for Vertex Pharmaceuticals' products and services. The demand for its core products is generally driven by patient populations and medical need rather than significant seasonal fluctuations. New product launches and regulatory approvals are more likely to impact demand than seasonal patterns.

Vertex Pharmaceuticals, Inc. is a global biotechnology company focused on discovering, developing, and commercializing innovative medicines for serious diseases, particularly recognized for its advancements in treating cystic fibrosis (CF). Its major products for cystic fibrosis include TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, KALYDECO and ALYFTREK. Beyond CF, Vertex has expanded its portfolio to include therapies and programs for sickle cell disease, transfusion-dependent beta thalassemia, acute pain, neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1, alpha-1 antitrypsin deficiency and muscular dystrophies.

Vertex Pharmaceuticals has a global presence with research and development sites, manufacturing facilities, and offices around the world. Its global headquarters are in Boston, Massachusetts, with international headquarters in London. The company operates in North America, Europe, Australia, Latin America, and the Middle East, divided into two main geographic areas: the United States and outside of the United States.

Vertex Pharmaceuticals has consistently maintained a strong brand reputation, particularly within the scientific and employment communities. The company has been recognized as one of the industry's top places to work. Successful product launches, advancement of pipeline programs, and positive clinical data presentations have positively impacted Vertex's reputation. Challenges in certain pipeline programs and increased operational expenses have been noted as concerns.

Vertex Pharmaceuticals is primarily owned by institutional shareholders, who hold approximately 93.79% of the company's stock. Insiders own about 1.50%, and retail investors hold 4.71%. Capital World Investors is the largest individual shareholder, owning 11.21% of the company. Other major institutional owners include Vanguard Group Inc, BlackRock Inc, Capital Research Global Investors, State Street Corp, Fmr LLC, Jennison Associates LLC, Geode Capital Management LLC, Jpmorgan Chase Co and Wellington Management Group LLP.